In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is currently on FREE ACCESS, enjoy another 18 days of free consultation

In these unprecedented times, the ESC is doing everything it can to support its community: FREE access to all ESC 365 content until 31 July: explore more than 125,000 educational resources.

From 1 August onwards, support our mission by becoming a member.

Gut microbiota composition and interactions with diet: dysbiosis in heart failure is partly related to lower fiber intake

Session Young Investigator Award - Basic Science and Translational Science

Speaker Cristiane Mayerhofer

Event : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Heart Failure with Reduced Ejection Fraction
  • Session type : Young Investigator Award Abstracts

Authors : C Mayerhofer (Oslo,NO), M Kummen (Oslo,NO), K Holm (Oslo,NO), K Broch (Oslo,NO), A Awoyemi (Oslo,NO), B Vestad (Oslo,NO), C Storm-Larsen (Oslo,NO), I Seljeflot (Oslo,NO), T Ueland (Oslo,NO), P Bohov (Bergen,NO), RK Berge (Bergen,NO), A Svardal (Bergen,NO), L Gullestad (Oslo,NO), JR Hov (Oslo,NO), M Troseid (Oslo,NO)

Authors:
C Mayerhofer1 , M Kummen2 , K Holm2 , K Broch1 , A Awoyemi3 , B Vestad2 , C Storm-Larsen2 , I Seljeflot3 , T Ueland2 , P Bohov4 , RK Berge4 , A Svardal4 , L Gullestad1 , JR Hov2 , M Troseid5 , 1Oslo University Hospital, Department of Cardiology Rikshospitalet - Oslo - Norway , 2Oslo University Hospital, Research Institute of Internal Medicine - Oslo - Norway , 3Oslo University Hospital, Department of Cardiology Ullevål - Oslo - Norway , 4University of Bergen - Bergen - Norway , 5Oslo University Hospital, Section of Clinical Immunology and Infectious diseases - Oslo - Norway ,

Citation:

Objectives: To explore differences in the gut microbiota between patients with heart failure (HF) and healthy controls with a particular focus on associations with diet, etiology and disease severity. Background: Recent reports have suggested alterations in the gut microbiota of patients with HF. Associations with diet remain largely uninvestigated. Methods: The microbiota composition of two independent, cross-sectional cohorts (discovery, n=40 and validation, n=44) of patients with systolic HF and healthy controls (n=266) were characterized by sequencing of the bacterial 16S rRNA gene. Dietary and metabolite data were available for the validation cohort and follow-up data were available for the discovery cohort. Results: The overall microbial community (beta diversity) differed between patients with HF and healthy controls in both cohorts (P<0.05). Patients with HF had a lower Firmicutes/Bacteroidetes (F/B)-ratio than controls (P=0.005), with a decreasing trend going from healthy controls via ischemic HF to non-ischemic HF (p for trend <0.05). Patients reaching a clinical endpoint (heart transplant or death) showed lower alpha diversity and lower F/B-ratio compared to healthy controls (P<0.01). Meat intake was associated with levels of trimethylamine-N-oxide (P=0.016). Finally, bacterial richness and abundance of several genera in the Firmicutes phylum were positively associated with fiber intake. Conclusions: The gut microbiota composition in chronic HF was characterized by a decreased F/B ratio, which was associated with etiology and clinical outcome. The dysbiosis in patients with HF was related to low fiber intake, thus dietary patterns should be included in future studies, both as covariates and potential treatment targets.



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are